| COMMENTS |
The pharmaceutical research community has already pricked up its ears, says Christopher A. Lipinski, a computational chemist with Pfizer Global Research & Development. Since the paper was published online in early March, he notes, three groups at Pfizer have passed it around. "You're talking about the ability, potentially, to save months to years of time," he says. The aggregates' structures, as well as why and how often molecules form them, are still mysteries. But ultimately, Lipinski says, the work should begin to address "a fundamental problem that's been plaguing people for a long time."
|